Trial Profile
COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms COSIMO
- Sponsors Bayer
- 02 Sep 2020 Results (n=163) assessing Patient Preferences Using a Discrete Choice Experiment published in the Thrombosis and Haemostasis
- 06 Nov 2019 Results of assessing clinical characteristics and patterns of use of anticoagulants, released in 61st Annual Meeting and Exposition of the American Society of Hematology
- 08 Apr 2019 Status changed from active, no longer recruiting to completed.